Earlier Presentation and Application of Curative Treatments in Hepatocellular Carcinoma

被引:80
作者
Ulahannan, Susanna V. [1 ]
Duffy, Austin G. [1 ]
McNeel, Timothy S. [2 ]
Kish, Jonathan K. [3 ]
Dickie, Lois A. [3 ]
Rahma, Osama E. [1 ]
McGlynn, Katherine A. [4 ]
Greten, Tim F. [1 ]
Altekruse, Sean F.
机构
[1] NCI, Gastrointestinal Malignancies Sect, Thorac & GI Oncol Branch, Bethesda, MD 20892 USA
[2] Informat Management Serv Inc, Calverton, MD USA
[3] NCI, Div Canc Control & Populat Sci, Rockville, MD USA
[4] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA
关键词
RADIOFREQUENCY ABLATION; SURGICAL RESECTION; SURVEILLANCE; SURVIVAL; TRIAL; CHEMOEMBOLIZATION; CIRRHOSIS;
D O I
10.1002/hep.27288
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The purpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in the population. HCC treatment patterns were examined in Surveillance, Epidemiology, and End Results (SEER) 18 registries (28% of U.S.). Joinpoint regression analyses were performed to assess 2000-2010 incidence trends by tumor size, count, and receipt of potentially curative treatments (transplantation, resection, and ablation). SEER-Medicare data enabled evaluation of treatment patterns including receipt of sorafenib or transarterial chemoembolization (TACE) by HCC-associated comorbidities. Diagnoses of tumors <= 5.0 cm in diameter significantly increased during 2000-2010, surpassing diagnosis of larger tumors. Overall, 23% of cases received potentially curative treatment. Joinpoint models indicated incidence rates of treatment with curative intent increased 17.6% per year during 2000-2005, then declined by -2.9% per year during 2005-2010 (P < 0.001). Among HCC cases with a single tumor <= 5.0 cm and no extension beyond the liver, use of ablative therapy significantly increased during 2000-2010. Use of invasive surgery for single tumors, regardless of size, significantly increased during the initial years of the decade, then plateaued. The group most likely to receive curative treatment in the SEER-Medicare cases was patients with one, small tumor confined to the liver (657 of 1,597 cases, 41%), with no difference in treatment by hepatic comorbidity status (P = 0.24). A higher proportion of cases with reported liver-associated comorbidities were, however, diagnosed with tumors <= 5.0 cm in diameter (1,745 0f 2,464, 71%) compared to patients with no reported comorbidities (996 of 2,596, 38%, P < 0.001). Conclusion: Although more HCC patients were diagnosed with early disease over time, the use of curative treatments in this patient group has recently plateaued. Efforts to identify and treat more eligible candidates for curative therapy could be beneficial.
引用
收藏
页码:1637 / 1644
页数:8
相关论文
共 27 条
[1]   Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[2]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[3]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[4]   Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design [J].
Burrel, Marta ;
Reig, Maria ;
Forner, Alejandro ;
Barrufet, Marta ;
Rodriguez de Lope, Carlos ;
Tremosini, Silvia ;
Ayuso, Carmen ;
Llovet, Josep M. ;
Isabel Real, Maria ;
Bruix, Jordi .
JOURNAL OF HEPATOLOGY, 2012, 56 (06) :1330-1335
[5]   Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate [J].
Cescon, Matteo ;
Cucchetti, Alessandro ;
Ravaioli, Matteo ;
Pinna, Antonio Daniele .
JOURNAL OF HEPATOLOGY, 2013, 58 (03) :609-618
[6]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[7]   Use of Surveillance for Hepatocellular Carcinoma Among Patients With Cirrhosis in the United States [J].
Davila, Jessica A. ;
Morgan, Robert O. ;
Richardson, Peter A. ;
Du, Xianglin L. ;
McGlynn, Katherine A. ;
El-Serag, Hashem B. .
HEPATOLOGY, 2010, 52 (01) :132-141
[8]   Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA [J].
El-Serag, Hashem B. ;
Kramer, Jennifer R. ;
Chen, G. John ;
Duan, Zhigang ;
Richardson, Peter A. ;
Davila, Jessica A. .
GUT, 2011, 60 (07) :992-997
[9]  
Ferlay J., 2013, IARC CancerBase
[10]  
Fritz A, 2000, INT CLASSIFICATION D